Accès gratuit
Numéro
Med Sci (Paris)
Volume 18, Numéro 4, Avril 2002
Page(s) 398 - 400
Section Le Magazine : Nouvelles
DOI http://dx.doi.org/10.1051/medsci/2002184398
Publié en ligne 15 avril 2002
  1. Jiang XC, Bruce C, Mar J, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103 : 907–14.
  2. Jiang XC, Qin S, Qiao C, et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001; 7 : 847–52.
  3. Albers JJ, Tu AY, Paigen B, Chen H, Cheung MC, Marcovina SM. Transgenic mice expressing human phospholipid transfer protein have increased HDL/non-HDL cholesterol ratio. Int J Clin Lab Res 1996; 26 : 262–7.
  4. Van Haperen R, van Tol A, Vermeulen P, et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000; 20 : 1082–8.
  5. Desrumaux C, Deckert V, Athias A, et al. Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering alpha-tocopherol to endothelial cells. FASEB J 1999; 13 : 883–92.
  6. Jiang XC, Qin S, Lin M, et al. Phospholipid transfer protein (PLTP) deficiency represents an anti-oxidant state in mice. Circulation 2001; 104 : II–232.